Evaluating blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as Merkel cell carcinoma biomarkers

Oncotarget

Volumn 6, Issue 28, 2015, Pages 26472-26482

  Gaiser, Maria Rita ^a   Daily, Kenneth ^b   Hoffmann, Jochen ^a   Brune, Maik ^a   Enk, Alexander ^a   Brownell, Isaac ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chromogranin A; Circulating tumor cells; EpCAM; Merkel cell carcinoma; Neuron specific enolase

Indexed keywords

CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; TUMOR MARKER; CHGA PROTEIN, HUMAN; ENOLASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CIRCULATING TUMOR CELL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE SPECIFIC SURVIVAL; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MERKEL CELL TUMOR; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR RECURRENCE; VERY ELDERLY; BLOOD; CARCINOMA, MERKEL CELL; CELL COUNT; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; RISK FACTOR; SKIN NEOPLASMS; TUMOR EMBOLISM; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, MERKEL CELL; CELL COUNT; CHROMOGRANIN A; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; PHOSPHOPYRUVATE HYDRATASE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; UP-REGULATION;

EID: 84944463430     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4500     Document Type: Article

References (56)

1. Schrama D, Becker JC. Merkel cell carcinoma-pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol. 2011; 25:1121-1129.
2. Nicolaidou E, Mikrova A, Antoniou C, Katsambas AD. Advances in Merkel cell carcinoma pathogenesis and management: a recently discovered virus, a new international consensus staging system and new diagnostic codes. Br J Dermatol. 2012; 166:16-21.
3. Tai P. Merkel cell cancer: update on biology and treatment. Curr Opin Oncol. 2008; 20:196-200.
4. Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010; 63:751-761.
5. Kittaneh M, Montero AJ, Gluck S. Molecular profiling for breast cancer: a comprehensive review. Biomarkers in cancer. 2013; 5:61-70.
6. Zeestraten EC, Benard A, Reimers MS, Schouten PC, Liefers GJ, van de Velde CJ, Kuppen PJ. The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry. Biomarkers in cancer. 2013; 5:13-29.
7. Granberg D, Stridsberg M, Seensalu R, Eriksson B, Lundqvist G, Oberg K, Skogseid B. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1999; 84:2712-2717.
8. O'Connor DT, Deftos LJ. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med. 1986; 314:1145-1151.
9. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival. J Clin Invest. 1990; 85:1555-1559.
10. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, Young B, Wailoo AJ, Burchill SA. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004; 10:4-12.
11. Burghuber OC, Worofka B, Schernthaner G, Vetter N, Neumann M, Dudczak R, Kuzmits R. Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Cancer. 1990; 65:1386-1390.
12. Portela-Gomes GM, Hacker GW, Weitgasser R. Neuroendocrine cell markers for pancreatic islets and tumors. Appl Immunohistochem Mol Morphol. 2004; 12:183-192.
13. Becker J, Mauch C, Kortmann RD, Keilholz U, Bootz F, Garbe C, Hauschild A, Moll I. Short German guidelines: Merkel cell carcinoma. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG. 2008; 1:S15-16.
14. National Comprehensive Cancer Network-Clinical Practice Guidelines in Oncology (NCCN Guidelines): Merkel cell carcinoma. 2015. http://www.merkelcell.org/usefulInfo/index.php. Accessed 13 May 2015.
15. Zhe X, Cher ML, Bonfil RD. Circulating tumor cells: finding the needle in the haystack. Am J Cancer Res. 2011; 1:740-751.
16. Friedlander TW, Premasekharan G, Paris PL. Looking back, to the future of circulating tumor cells. Pharmacol Ther. 2013; 142:271-80.
17. Pantel K and Alix-Panaberes C. Real-time liquid biopsy in cancer patients: fact or fiction? Cancer Res. 2013; 73:6384-6388.
18. Schulze K, Gasch C, Staufer K, Nashan B, Lohse AW, Pantel K, Riethdorf S, Wege H. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer. 2013; 133:2165-2171.
19. Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Jorke C, Hammer U, Altendorf-Hofmann A, Rabenstein C, Pachmann U, Runnebaum I, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol. 2008; 26:1208-1215.
20. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007; 171:386-395.
21. Kurzen H, Kaul S, Egner U, Deichmann M, Hartschuh W. Expression of MUC 1 and Ep-CAM in Merkel cell carcinomas: implications for immunotherapy. Archives of dermatological research. 2003; 295:146-154.
22. Giannone L, Johnson DH, Grosh WW, Davis BW, Marangos PJ, Greco FA. Serum neuron-specific enolase in metastatic Merkel cell tumors. Med Pediatr Oncol. 1985; 13:357-362.
23. Gu J, Polak JM, Van Noorden S, Pearse AG, Marangos PJ, Azzopardi JG. Immunostaining of neuron-specific enolase as a diagnostic tool for Merkel cell tumors. Cancer. 1983; 52:1039-1043.
24. Plowman PN. Serum marker for Merkel cell tumour. Clin Radiol. 1989; 40:542.
25. Hall PA, d'Ardenne AJ, Butler MG, Stearn PM, Subbuswamy SG, Blackshaw AJ, Levison DA. Cytokeratin and laminin immunostaining in the diagnosis of cutaneous neuro-endocrine (Merkel cell) tumours. Histopathology. 1986; 10:1179-1190.
26. Wilson BS, Lloyd RV. Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. Am J Pathol. 1984; 115:458-468.
27. Battifora H, Silva EG. The use of antikeratin antibodies in the immunohistochemical distinction between neuroendocrine (Merkel cell) carcinoma of the skin, lymphoma, and oat cell carcinoma. Cancer. 1986; 58:1040-1046.
28. Nobels FR, Kwekkeboom DJ, Coopmans W, Schoenmakers CH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SW. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alphasubunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997; 82:2622-2628.
29. Cimitan M, Buonadonna A, Cannizzaro R, Canzonieri V, Borsatti E, Ruffo R, De Apollonia L. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2003; 14:1135-1141.
30. Haimoto H, Takahashi Y, Koshikawa T, Nagura H, Kato K. Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest. 1985; 52:257-263.
31. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004; 10:8152-8162.
32. Muller V, Alix-Panabieres C, Pantel K. Insights into minimal residual disease in cancer patients: implications for anti-cancer therapies. Eur J Cancer. 2010; 46:1189-1197.
33. Pachmann K, Heiss P, Demel U, Tilz G. Detection and quantification of small numbers of circulating tumour cells in peripheral blood using laser scanning cytometer (LSC). Clin Chem Lab Med. 2001; 39:811-817.
34. Fleisher TA, Marti GE. Detection of unseparated human lymphocytes by flow cytometry. Current protocols in immunology/ edited by John E Coligan, [et al]. 2001; Chapter 7:Unit 7 9.
35. Tam CS, Turner P, McLean C, Whitehead S, Cole-Sinclair M. 'Leukaemic' presentation of metastatic Merkel cell carcinoma. Br J Haematol. 2005; 129:446.
36. Nemoto I, Sato-Matsumura KC, Fujita Y, Natsuga K, Ujiie H, Tomita Y, Kato N, Kondo M, Ohnishi K. Leukaemic dissemination of Merkel cell carcinoma in a patient with systemic lupus erythematosus. Clin Exp Dermatol. 2008; 33:270-272.
37. Hartley MA, Tao J, Baz R. Merkel cell carcinoma in the peripheral blood of a patient with concomitant chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol. 2010; 28:e113-114.
38. Blom A, Bhatia S, Pietromonaco S, Koehler K, Iyer JG, Nagase K, Paulson K, Sabath DE, Nghiem P. Clinical utility of a circulating tumor cell assay in Merkel cell carcinoma. J Am Acad Dermatol. 2013.
39. Scriba TJ, Purbhoo M, Day CL, Robinson N, Fidler S, Fox J, Weber JN, Klenerman P, Sewell AK, Phillips RE. Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol. 2005; 175:6334-6343.
40. Pizon M, Zimon D, Carl S, Pachmann U, Pachmann K, Camara O. Heterogeneity of circulating epithelial tumour cells from individual patients with respect to expression profiles and clonal growth (sphere formation) in breast cancer. Ecancermedicalscience. 2013; 7:343.
41. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW. All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2010; 21:1851-1857.
42. Panteleakou Z, Lembessis P, Sourla A, Pissimissis N, Polyzos A, Deliveliotis C, Koutsilieris M. Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Molecular medicine. 2009; 15:101-114.
43. Gaiser MR, Lammermann T, Feng X, Igyarto BZ, Kaplan DH, Tessarollo L, Germain RN, Udey MC. Cancer- associated epithelial cell adhesion molecule (EpCAM; CD326) enables epidermal Langerhans cell motility and migration in vivo. Proc Natl Acad Sci U S A. 2012; 109:E889-897.
44. Hardingham JE, Hewett PJ, Sage RE, Finch JL, Nuttall JD, Kotasek D, Dobrovic A. Molecular detection of blood- borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer. 2000; 89:8-13.
45. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420:860-867.
46. Moll R, Franke WW. Cytoskeletal differences between human neuroendocrine tumors: a cytoskeletal protein of molecular weight 46, 000 distinguishes cutaneous from pulmonary neuroendocrine neoplasms. Differentiation. 1985; 30:165-175.
47. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol. 2013; 20:285-314.
48. Kurokawa M, Nabeshima K, Akiyama Y, Maeda S, Nishida T, Nakayama F, Amano M, Ogata K, Setoyama M. CD56: a useful marker for diagnosing Merkel cell carcinoma. J Dermatol Sci. 2003; 31:219-224.
49. Gallego R, Garcia-Caballero T, Fraga M, Beiras A, Forteza J. Neural cell adhesion molecule immunoreactivity in Merkel cells and Merkel cell tumours. Virchows Arch. 1995; 426:317-321.
50. LeBoit PE. "Magic bullets" in immunohistochemistry. Am J Dermatopathol. 2002; 24:518-520.
51. McNiff JM, Cowper SE, Lazova R, Subtil A, Glusac EJ. CD56 staining in Merkel cell carcinoma and natural killer-cell lymphoma: magic bullet, diagnostic pitfall, or both? J Cutan Pathol. 2005; 32:541-545.
52. Jung R, Petersen K, Kruger W, Wolf M, Wagener C, Zander A, Neumaier M. Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer. 1999; 81:870-873.
53. Imamura N, Kusunoki Y, Kajihara H, Okada K, Kuramoto A. Aggressive natural killer cell leukemia/lymphoma with N901-positive surface phenotype: evidence for the existence of a third lineage in lymphoid cells. Acta haematologica. 1988; 80:121-128.
54. Bustin SA, Gyselman VG, Siddiqi S, Dorudi S. Cytokeratin 20 is not a tissue-specific marker for the detection of malignant epithelial cells in the blood of colorectal cancer patients. International journal of surgical investigation. 2000; 2:49-57.
55. Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010; 16:398-406.
56. Pachmann K, Clement JH, Schneider CP, Willen B, Camara O, Pachmann U, Hoffken K. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med. 2005; 43:617-627.